The role of the opioid system in alcohol dependence

Journal of Psychopharmacology

Volumn 28, Issue 1, 2014, Pages 8-22

  Nutt, David J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

addiction; alcohol; Brain opioid system; dependence; opiates; receptor; review

Indexed keywords

ACAMPROSATE; BETA FUNALTREXAMINE; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; DELTA OPIATE RECEPTOR ANTAGONIST; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLORNITHYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; DIPRENORPHINE; DISULFIRAM; ENDORPHIN; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; GABAPENTIN; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; KAPPA OPIATE RECEPTOR ANTAGONIST; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR ANTAGONIST; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; N,N DIALLYLTYROSYL 2 METHYLALANYL 2 METHYLALANYLPHENYLALANYLLEUCINE; NALMEFENE; NALOXONAZINE; NALOXONE; NALTREXONE; NALTRIBEN; NALTRINDOLE; NORBINALTORPHIMINE; PLACEBO; PROENKEPHALIN; UNINDEXED DRUG; NARCOTIC ANTAGONIST; OPIATE RECEPTOR;

4 AMINOBUTYRIC ACID RELEASE; ABNORMAL BLOOD PRESSURE; AGITATION; ALCOHOL CONSUMPTION; ALCOHOL METABOLISM; ALCOHOL TOLERANCE; ALCOHOL WITHDRAWAL; ALCOHOLISM; AVERSION; BINDING AFFINITY; BODY TEMPERATURE DISORDER; CARDIOVASCULAR DISEASE; COGNITIVE THERAPY; DIARRHEA; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DROWSINESS; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SEEKING BEHAVIOR; FLUSHING; GASTROINTESTINAL DISEASE; GENETIC PREDISPOSITION; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; IMPULSIVENESS; LIMBIC SYSTEM; LONG TERM POTENTIATION; MONOTHERAPY; NAUSEA; NONHUMAN; NUCLEUS ACCUMBENS; PLACE PREFERENCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECOMMENDED DRUG DOSE; REINFORCEMENT; RELAPSE; REVIEW; REWARD; SINGLE DRUG DOSE; SYNAPTIC TRANSMISSION; TISSUE DISTRIBUTION; VENTRAL TEGMENTUM; VOMITING; WITHDRAWAL SYNDROME; BEHAVIOR, ADDICTIVE; BRAIN; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALCOHOLISM; BEHAVIOR, ADDICTIVE; BRAIN; HUMANS; IMPULSIVE BEHAVIOR; NARCOTIC ANTAGONISTS; RECEPTORS, OPIOID;

EID: 84891876881     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881113504017     Document Type: Review

References (204)

1. Adinoff B, Krebaum SR, Chandler PA, et al. Dissection of hypothalamic-pituitary-adrenal axis pathology in 1-month-abstinent alcohol-dependent men, part 2: Response to ovine corticotropin-releasing factor and naloxone. Alcohol Clin Exp Res. 2005 ; 29: 528-537 (Pubitemid 40547855)
2. Altshuler HL, Phillips PE, Feinhandler DA. Alteration of ethanol self-administration by naltrexone. Life Sci. 1980 ; 26: 679-688 (Pubitemid 10067965)
3. Anokhina IP, Ivanets NN, Burov YV, et al. Alcohol and alcohol problems research 13: U.S.S.R. Br J Addict. 1987 ; 82: 23-30
4. Anton RF, Moak DH, Waid LR, et al. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: Results of a placebo-controlled trial. Am J Psychiat. 1999 ; 156: 1758-1764 (Pubitemid 29517569)
5. Anton RF, Myrick H, Wright TM, et al. Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiat. 2011 ; 168: 709-717
6. Asali LA, Brown KF. Naloxone protein binding in adult and foetal plasma. Eur J Clin Pharmacol. 1984 ; 27: 459-463 (Pubitemid 15217762)
7. Bart G, Schluger JH, Borg L, et al. Nalmefene induced elevation in serum prolactin in normal human volunteers: Partial kappa opioid agonist activity. Neuropsychopharmacol. 2005 ; 30: 2254-2262 (Pubitemid 41643977)
8. Bazov I, Kononenko O, Watanabe H, et al. The endogenous opioid system in human alcoholics: Molecular adaptations in brain areas involved in cognitive control of addiction. Addict Biol. 2013 ; 18: 161-169
9. Benjamin D, Grant ER, Pohorecky LA. Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats. Brain Res. 1993 ; 621: 137-140 (Pubitemid 23242172)
10. Berkowitz BA. The relationship of pharmacokinetics to pharmacological activity: Morphine, methadone and naloxone. Clin Pharmacokinet. 1976 ; 1: 219-230
11. Bierut LJ. Genetic vulnerability and susceptibility to substance dependence. Neuron. 2011 ; 69: 618-627
12. Blednov YA, Walker D, Martinez M, et al. Reduced alcohol consumption in mice lacking preprodynorphin. Alcohol. 2006 ; 40: 73-86 (Pubitemid 46329324)
13. Blum K, Briggs AH, Wallace JE, et al. Regional brain [met]-enkephalin in alcohol-preferring and non-alcohol-preferring inbred strains of mice. Experientia. 1987 ; 43: 408-410 (Pubitemid 17060939)
14. Boettiger CA, Kelley EA, Mitchell JM, et al. Now or later? An fMRI study of the effects of endogenous opioid blockade on a decision-making network. Pharmacol Biochem Behav. 2009 ; 93: 291-299
15. Bruijnzeel AW. Kappa-opioid receptor signalling and brain reward function. Brain Res Rev. 2009 ; 62: 127-146
16. Chang G, Barson JR, Karatayev O, et al. Effect of chronic ethanol on enkephalin in the hypothalamus and extra-hypothalamic areas. Alcohol Clin Exp Res. 2010 ; 34: 761-770
17. Chesselet MF, Cheramy A, Reisine TD, et al. Local and distal effects induced by unilateral striatal application of opioids in the absence or in the presence of naloxone on the release of dopamine in both caudate nuclei and the substantiae nigrae of the cat. Brain Res. 1983 ; 258: 229-242 (Pubitemid 13211744)
18. Chick J, Anton R, Checinski K, et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. 2000 ; 35: 587-593
19. Ciccocioppo R, Martin-Fardon R, Weiss F. Effect of selective blockade of mu(1) or delta opioid receptors on reinstatement of alcohol-seeking behavior by drug-associated stimuli in rats. Neuropsychopharmacol. 2002 ; 27: 391-399 (Pubitemid 35256145)
20. Cloninger CR. Neurogenetic adaptive mechanisms in alcoholism. Science. 1987 ; 236: 410-416 (Pubitemid 17071986)
21. Colasanti A, Searle GE, Long CJ, et al. Endogenous opioid release in the human brain reward system induced by acute amphetamine administration. Biol Psychiatry. 2012 ; 72: 371-377
22. Contet C, Kieffer BL, Befort K. Mu opioid receptor: A gateway to drug addiction. Curr Opin Neurobiol. 2004 ; 14: 370-378 (Pubitemid 38759868)
23. Cowan A, Zhu XZ, Mosberg HI, et al. Direct dependence studies in rats with agents selective for different types of opioid receptor. J Pharm Exp Therap. 1988 ; 246: 950-955
24. Croop RS, Faulkner EB, Labriola DF. The safety profile of naltrexone in the treatment of alcoholism. Arch Gen Psych. 1997 ; 54: 1130-1135
25. D'Addario C, Caputi FF, Rimondini R, et al. Different alcohol exposures induce selective alterations on the expression of dynorphin and nociceptin systems related genes in rat brain. Addict Biol. 2013 ; 18: 425-433
26. Daglish MR, Weinstein A, Malizia AL, et al. Functional connectivity analysis of the neural circuits of opiate craving: 'More' rather than 'different'?. Neuroimage. 2003 ; 20: 1964-1970 (Pubitemid 37543614)
27. Davidson D, Palfai T, Bird C, et al. Effects of naltrexone on alcohol self-adminstration in heavy drinkers. Alcohol Clin Exp Res. 1999 ; 23: 195-203 (Pubitemid 29100390)
28. Davidson D, Swift R, Fitz E. Naltrexone increases the latency to drink alcohol in social drinkers. Alcohol Clin Exp Res. 1996 ; 20: 732-739 (Pubitemid 26186942)
29. De Brabander B, Declerck CH. A possible role of central dopamine metabolism associated with individual differences in locus of control. Pers Individ Dif. 2004 ; 37: 735-750 (Pubitemid 39072499)
30. De Waele J, Gianoulakis C. Effects of single and repeated exposures to ethanol on hypothalamic β-endorphin and CRH release by the C57BL/6 and DBA/2 strains of mice. Neuroendocrinology. 1993 ; 57: 700-709 (Pubitemid 23223637)
31. Devine DP, Leone P, Pocock D, et al. Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: In vivo microdialysis studies. J Pharmacol Exp Ther. 1993 ; 266: 1236-1246 (Pubitemid 24175764)
32. Devine P, Wise R. Self-administration ventral tegmental of morphine, DAMGO, and DPDPE into the area of rats. J Neurosci. 1994 ; 14: 1978-1984 (Pubitemid 24108108)
33. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci. 1988a ; 85: 5274-5278
34. Di Chiara G, Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther. 1998b ; 244: 1067-1080
35. Di Chiara G, North R. Neurobiology of opiate abuse. Trends Pharm Sci. 1992 ; 13: 185-193
36. Dixon R, Gentile J, Hsu HB, et al. Nalmefene: Safety and kinetics after single and multiple oral doses of a new opioid antagonist. J Clin Pharmacol. 1987 ; 27: 233-239 (Pubitemid 18026908)
37. Dixon R, Howes J, Gentile J, et al. Nalmefene: Intravenous safety and kinetics of a new opioid antagonist. Clin Pharmacol Ther. 1986 ; 39: 49-53 (Pubitemid 16166965)
38. Drobes DJ, Anton RF, Thomas SE, et al. A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: Naltrexone and nalmefene. Neuropsychopharmacol. 2003 ; 28: 755-764
39. Drobes DJ, Anton RF, Thomas SE, et al. Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res. 2004 ; 28: 1362-1370 (Pubitemid 39238295)
40. Ducci F, Goldman D. Genetic approaches to addiction: Genes and alcohol. Addiction. 2008 ; 103: 1414-1428
41. Dumont M, Lemaire S. Interaction of dynorphin with kappa opioid receptors in bovine adrenal medulla. Neuropeptide. 1985 ; 6: 321-329 (Pubitemid 15021860)
42. Dymshitz J, Lieblich I. Opiate reinforcement and naloxone aversion, as revealed by place preference paradigm, in two strains of rats. Psychopharmacology(Berl). 1987 ; 92: 473-477 (Pubitemid 17105245)
43. Emmerson PJ, Liu MR, Woods JH, et al. Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. J Pharmacol Exp Ther. 1994 ; 271: 1630-1637 (Pubitemid 24382680)
44. Femenía T, Manzanares J. Increased ethanol intake in prodynorphin knockout mice is associated to changes in opioid receptor function and dopamine transmission. Addict Biol. 2012 ; 17: 322-337
45. Flory JD, Pytte CL, Hurd Y, et al. Alcohol dependence, disinhibited behavior and variation in the prodynorphin gene. Biol Psychol. 2011 ; 88: 51-56
46. Frye RF, Matzke GR, Schade R, et al. Effects of liver disease on the disposition of the opioid antagonist nalmefene. Clin Pharmacol Ther. 1997 ; 61: 15-23 (Pubitemid 27072880)
47. Fudala PJ, Heishman SJ, Henningfield JE, et al. Human pharmacology and abuse potential of nalmefene. Clin Pharmacol Ther. 1991 ; 49: 300-306
48. Gal TJ, DiFazio CA, Dixon R. Prolonged blockade of opioid effect with oral nalmefene. Clin Pharmacol Ther. 1986 ; 40: 537-542 (Pubitemid 17185088)
49. Gianoulakis C. Characterization of the effects of acute ethanol administration on the release of beta-endorphin peptides by the rat hypothalamus. Eur J Pharmacol. 1990 ; 180: 21-29 (Pubitemid 20140986)
50. Gianoulakis C. Endogenous opioids and excessive alcohol consumption. J Psychiat Neurosci. 1993 ; 18: 148-156 (Pubitemid 23255880)
51. Gianoulakis C, Barcomb A. Effect of acute ethanol in vivo and in vitro on the β-endorphin system in the rat. Life Sci. 1987 ; 40: 19-28 (Pubitemid 17226120)
52. Gonzales R, Jaworski J. Alcohol and glutamate. Alcohol Health Res World. 1997 ; 21: 120-127 (Pubitemid 127709490)
53. Gonzales R, Weiss F. Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. J Neurosci. 1998 ; 18: 10663-10671 (Pubitemid 29016583)
54. Gouarderes C, Cros J, Quirion R. Autoradiographic localization of mu, delta and kappa opioid receptor binding sites in rat and guinea pig spinal cord. Neuropeptides. 1985 ; 6: 331-342 (Pubitemid 15021861)
55. Gual A, He Y, Torup L, et al. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol. 2013 ;:
56. Hayward MD, Schnaich-Borg A, Pintar JE, et al. Differential involvement of endogenous opioids in sucrose consumption and food reinforcement. Pharmacol Biochem Behav. 2006 ; 85: 601-611 (Pubitemid 46097071)
57. Heilig M, Koob G. A key role for corticotropin-releasing factor in alcohol dependence. Trends Neurosci. 2007 ; 30: 399-406 (Pubitemid 47090230)
58. Heimer L, Switzer RD, van Hoesen GW. Ventral striatum and ventral pallidum: Components of the motor system. Trends Neurosci. 1982 ; 5: 83-87
59. Heinala P, Alho H, Kiianmaa K, et al. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: A factorial double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2001 ; 21: 287-292 (Pubitemid 32452933)
60. Heinz A, Lober S, Georgi A, et al. Reward craving and withdrawal relief craving: Assessment of different motivational pathways to alcohol intake. Alcohol Alcohol. 2003 ; 38: 35-39 (Pubitemid 36204362)
61. Heinz A, Reimold M, Wrase J, et al. Correlation of stable elevations in striatal μ-opioid receptor availability in detoxified alcoholic patients with alcohol craving. Arch Gen Psychiat. 2005 ; 62: 57-64
62. Henriksen G, Willoch F. Imaging of opioid receptors in the central nervous system. Brain. 2008 ; 131: 1171-1196
63. Herz A. Endogenous opioid systems and alcohol addiction. Psychopharmacology(Berl). 1997 ; 129: 99-111 (Pubitemid 27033665)
64. Houtani T, Nishi M, Takeshima H, et al. Distribution of nociceptin/orphanin FQ precursor protein and receptor in brain and spinal cord: A study using in situ hybridization and X-gal histochemistry in receptor-deficient mice. J Comp Neurol. 2000 ; 424: 489-508 (Pubitemid 30670446)
65. Huge V, Rammes G, Beyer A, et al. Activation of kappa opioid receptors decreases synaptic transmission and inhibits long-term potentiation in the basolateral amygdala of the mouse. Eur J Pain. 2009 ; 13: 124-129
66. Hyytia P. Involvement of mu-opioid receptors in alcohol drinking by alcohol-preferring AA rats. Pharmacol Biochem Behav. 1993 ; 45: 697-701
67. Hyytia P, Sinclair JD. Responding for oral ethanol after naloxone treatment by alcohol-preferring AA rats. Alcohol Clin Exp Res. 1993 ; 17: 631-636 (Pubitemid 23178449)
68. Ingman K, Hagelberg N, Aalto S, et al. Prolonged central μ-opioid receptor occupancy after single and repeated nalmefene dosing. Neuropsychopharmacol. 2005 ; 30: 2245-2253 (Pubitemid 41643976)
69. Iovcheva M, Zlateva S, Asparuhova MS. Precipitated withdrawal reaction to opiates in cases of improper use of naltrexone. Addict Biol. 2007 ; 1: 75-77
70. Johnson N, Houghten R, Pasternak GW. Binding of [3H]-β-endorphin in rat brain. Life Sci. 1982 ; 31: 1381-1384
71. June HL, Cummings R, Eiler WJA, et al. Central opioid receptors differentially regulate the nalmefene-induced suppression of ethanol- and saccharin-reinforced behaviours in alcohol-preferring (P) rats. Neuropsychopharmacol. 2004 ; 29: 285-299 (Pubitemid 38175147)
72. June HL, Grey C, Warren-Reese C, et al. The opioid receptor antagonist nalmefene reduces responding behaviour maintained by ethanol presentation: Preclinical studies in ethanol-preferring and outbred Wistar rats. Alcohol Clin Exp Res. 1998 ; 22: 2174-2185 (Pubitemid 29031040)
73. June HL, McCane SR, Zink RW, et al. The δ2-opioid receptor antagonist naltriben reduces motivated responding for ethanol. Psychopharmacology (Berl). 1999 ; 147: 81-89 (Pubitemid 30010027)
74. Kakidani H, Furutani Y, Takahashi H, et al. Cloning and sequence analysis of cDNA for porcine B-neo-endorphin/dynorphin precursor. Nature. 1982 ; 298: 245-249 (Pubitemid 12089406)
75. Karahanian E, Quintanilla ME, Tampier L, et al. Ethanol as a prodrug: Brain metabolism of ethanol mediates its reinforcing effects. Alcohol Clin Exp Res. 2011 ; 35: 606-612
76. Kendler KS, Jacobson KC, Prescott CA, et al. Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins. Am J Psychiatry. 2003 ; 160: 687-695 (Pubitemid 41079601)
77. Kim S, Wagner HN, Villemagne VL, et al. Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system. J Nucl Med. 1997 ; 38: 1726-1731 (Pubitemid 27495519)
78. King AC, Volpicelli JR, Frazer A, et al. Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology (Berl). 1997 ; 129: 15-22 (Pubitemid 27037445)
79. Kitchen I, Slowe SJ, Matthes HWD, et al. Quantitative autoradiographic mapping of μ-,δ- and κ-opioid receptors in knockout mice lacking the u-opioid receptor gene. Brain Res. 1997 ; 778: 73-88 (Pubitemid 28039890)
80. Klein G, Juni A, Arout C, et al. Acute and chronic heroin dependence in mice: Contribution of opioid and excitatory amino acid receptors. Eur J Pharmacol. 2008 ; 586: 179-188
81. Koob GF. Animal models in craving research: Animal models of craving for alcohol. Addiction. 2000 ; 95: S73 - S81
82. Kovacs KM, Szakall I, O'Brien D, et al. Decreased oral self-administration of alcohol in kappa-opioid receptor knock-out mice. Alcohol Clin Exp Res. 2005 ; 29: 730-738 (Pubitemid 40686541)
83. Kranzler HR, Modesto-lowe V, Kirk J. Naltrexone vs nefazodone for treatment of alcohol dependence. Neuropsychopharmacol. 2000 ; 22: 493-503 (Pubitemid 30145617)
84. Kranzler HR, Modesto-Lowe V, Nuwayser ES. Sustained-release naltrexone for alcoholism treatment: A preliminary study. Alcohol Clin Exp Res. 1998 ; 22: 1074-1079 (Pubitemid 28408999)
85. Kreek MJ, Schluger J, Borg L, et al. Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: Gender differences and implications for modulation of dopaminergic tone in the treatment of addictions. J Pharmacol Exp Ther. 1999 ; 288: 260-269 (Pubitemid 29113499)
86. Krishnan-Sarin S, Jing SL, Kurtz DL, et al. The delta opioid receptor antagonist naltrindole attenuates both alcohol and saccharin intake in rats selectively bred for alcohol preference. Psychopharmacology (Berl). 1995a ; 120: 177-185
87. Krishnan-Sarin S, Portoghese PS, Li T, et al. The delta 2-opioid receptor antagonist naltriben selectively attenuates alcohol intake in rats bred for alcohol preference. Pharmacol Biochem Behav. 1995b ; 52: 153-159
88. Krishnan-Sarin S, Wand GS, Li XW, et al. Effect of mu opioid receptor blockade on alcohol intake in rats bred for high alcohol drinking. Pharmacol Biochem Behav. 1998 ; 59: 627-635 (Pubitemid 28144202)
89. Lam MP, Marinelli PW, Bai L, et al. Effects of acute ethanol on opioid peptide release in the central amygdala: An in vivo microdialysis study. Psychopharmacology (Berl). 2008 ; 201: 261-271
90. Lapham S, Forman R, Alexander M, et al. The effects of extended-release naltrexone on holiday drinking in alcohol dependent patients. J Subst Abuse Treat. 2008 ; 36: 1-6
91. Law P, Loh HH, Li CH. Properties and localization of B-endorphin receptor in rat brain. Proc Natl Acad Sci. 1979 ; 76: 5455-5459 (Pubitemid 10161641)
92. Le Merrer J, Becker JAJ, Befort K, et al. Reward processing by the opioid system in the brain. Physiol Rev. 2009 ; 89: 1379-1412
93. Lee MC, Wagner HN, Tanada S, et al. Duration of occupancy of opiate receptors by naltrexone. J Nucl Med. 1988 ; 29: 1207-1211
94. Linseman M, Le AD. Effects of opioids on the absorption of alcohol. Pharmacol Biochem Behav. 1997 ; 58: 79-84 (Pubitemid 27334356)
95. Littleton J. Animal models in craving research: Can craving be modelled in animals? The relapse prevention perspective. Addiction. 2000 ; 95: S83 - S90
96. Lord JAH, Waterfield AA, Hughes J, et al. Endogenous opioid peptides: Multiple agonists and receptors. Nature. 1977 ; 267: 495-499 (Pubitemid 8098466)
97. Mangold D, McCaul ME, Ali M, et al. Plasma adrenocorticotropin responses to opioid blockade with naloxone: Generating a dose-response curve in a single session. Biol Psychiatry. 2000 ; 48: 310-314 (Pubitemid 30645801)
98. Mann K, Bladström A, Torup L, et al. Extending the treatment options in alcohol dependence: A randomized controlled study of as-needed nalmefene. Biol Psychiatry. 2013 2013 ; 73: 706-713
99. Mann K, Kiefer F, Spanagel R, et al. Acamprosate: Recent findings and future research directions. Alcohol Clin Exp Res. 2008 ; 32: 1105-1110
100. Mansour A, Fox CA, Akil H, et al. Opioid-receptor mRNA expression in the rat CNS: Anatomical and functional implications. Trends Neurosci. 1995 ; 18: 22-29
101. Mansour A, Khachaturian H, Lewis ME, et al. Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain. J Neurosci. 1987 ; 7: 2445-2464
102. Marfaing-Jallat P, Miceli D, Le Magnen J. Decrease in ethanol consumption by naloxone in naive and dependent rats. Pharmacol Biochem Behav. 1983 ; 18: S537 - S539
103. Margolis EB, Hjelmstad GO, Bonci A, et al. Kappa-opioid agonists directly inhibit midbrain dopaminergic neurons. J Neurosci. 2003 ; 23: 9981-9986 (Pubitemid 37392543)
104. Marinelli PW, Lam M, Bai L, et al. A microdialysis profile of dynorphin A(1-8) release in the rat nucleus accumbens following alcohol administration. Alcohol Clin Exp Res. 2006 ; 30: 982-990 (Pubitemid 43823259)
105. Mark TL, Kassed CA, Vandivort-Warren R, et al. Alcohol and opioid dependence medications: Prescription trends, overall and by physician specialty. Drug Alcohol Depend. 2009 ; 99: 345-349
106. Martin WR, Eades CG, Thompson JA, et al. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharm Exp Ther. 1976 ; 197: 517-532
107. Martin WR, Jasinski DR, Mansky PA. Naltrexone, an antagonist for the treatment of heroin dependence. Arch Gen Psych. 1973 ; 28: 784-791
108. Mason BJ, Ritvo EC, Morgan RO, et al. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res. 1994 ; 18: 1162-1167 (Pubitemid 24345524)
109. Mason BJ, Salvato FR, Williams LD, et al. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psych. 1999 ; 56: 719-724 (Pubitemid 29357733)
110. Meng F, Xie G, Thompson RC, et al. Cloning and pharmacological characterization of a rat κ opioid receptor. Proc Natl Acad Sci. 1993 ; 90: 9954-9958 (Pubitemid 23328229)
111. Meunier J, Mollereau C, Toll L, et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature. 1995 ; 377: 532-535
112. Meyer MC, Straughn AB, Lo M, et al. Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. J Clin Psychiatry. 1984 ; 45: 15-19 (Pubitemid 14030105)
113. Michaelis EF, Michaelis ML, Freed WJ, et al. Glutamate receptor changes in brain synaptic membranes during chronic alcohol intake. Alcohol Alcohol. 1993 ;: S377 - S381
114. Michel ME, Bolger G, Weissman BA. Binding of a new opiate antagonist, nalmefene, to rat brain membranes. Methods Find Exp Clin Pharmacol. 1985 ; 7: 175-177 (Pubitemid 15068982)
115. Mihic S. Acute effects of ethanol on GABA A and glycine receptor function. Neurochem Int. 1999 ; 35: 115-123 (Pubitemid 29263067)
116. Mitchell JM, O'Neill JP, Janabi M, et al. Alcohol consumption induces endogenous opioid release in the human orbitofrontal cortex and nucleus accumbens. Sci Transl Med. 2012 ; 4: 1-8
117. Mitchell JM, Tavares VC, Fields HL, et al. Endogenous opioid blockage and impulsive response in alcoholics and healthy controls. Neuropsychopharmacology. 2007 ; 32: 439-449 (Pubitemid 46106950)
118. Mollereau C, Parmentier M, Mailleux P, et al. ORL1, a member of the opioid receptor family. FEBS Lett. 1994 ; 341: 33-38
119. Moos RH, Moos BS. Rates and predictors of relapse after natural and treated remission from alcohol use disorders. Addiction. 2006 ; 101: 212-222 (Pubitemid 43351596)
120. Morgan CJ, Badawy AA, Thomas R, et al. The [lactate]/[pyruvate] ratio and alcohol metabolism: Experiments with naloxone in fasting normal male volunteers. Alcohol Alcohol. 1989 ; 24: 185-188 (Pubitemid 19187572)
121. Mucha R, Herz A. Psychopharmacology Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning. Psychopharmacol. 1985 ; 86(3): 274-280 (Pubitemid 15064950)
122. Myers RD, McMillen BA, Adell A. Neurotransmitter and neuromodulatory mechanisms involved in alcohol abuse and alcoholism: Epitome of cerebral complexity. Neurochem Int. 1995 ; 26: 337-342
123. Nakanishi S, Inoue A, Kita T, et al. Nucleotide sequence of cloned cDNA for bovine corticotrophin-B-lipotrophin precursor. Nature. 1979 ; 278: 423-427 (Pubitemid 9130699)
124. Nalmefene hydrochloride summary of product characteristics. Available at: http://www.medicines.org.uk/emc/medicine/27609/SPC/ (accessed 3 September 2013).
125. Naltrexone hydrochloride summary of product characteristics. Available at: http://www.medicines.org.uk/emc/medicine/25878/SPC/(accessed 3 September 2013)
126. National Institute for Health and Clinical Excellence (2011) CG115. Alcohol use disorders: Diagnosis, assessment and management of harmful drinking and alcohol dependence. Available at: http://www.nice.org.uk/guidance/CG115 (accessed 18 October 2011).
127. National Institute on Alcohol Abuse and Alcoholism (2012) Naltrexone approved for alcoholism treatment. Available at: www.niaaa.nih.gov/news-events/ news-releases/naltrexone-approved-alcoholism-treatment (accessed 3 September 2013).
128. Neal CR, Mansour A, Reinscheid R, et al. Localisation of orphanin FQ (nociceptin) peptide and messenger RNA in the central nervous system of the rat. J Comp Neurobiol. 1999 ; 406: 503-547 (Pubitemid 29144937)
129. Nestler EJ. Genes and addiction. Nat Genet. 2000 ; 26: 277-281
130. Noda M, Furutani Y, Takahashi H, et al. Cloning and sequence analysis of cDNA for bovine adrenal preproenkephalin. Nature. 1982 ; 295: 202-206 (Pubitemid 12138496)
131. O'Leary G, Borrow J, Weiss RD. Opioid antagonists in the treatment of alcohol dependence. Curr Psychiat Rep. 2001 ; 3: 484-488
132. O'Malley S, Jaffe AJ, Chang G, et al. Naltrexone and coping skills therapy for alcohol dependence. Arch Gen Psych. 2002 ; 49: 881-887
133. O'Malley SS, Jaffe AJ, Chang G, et al. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry. 1992 ; 49: 881-887
134. Oberlin BG, Bristow RE, Heighton ME, et al. Pharmacologic dissociation between impulsivity and alcohol drinking in high alcohol preferring mice. Alcohol Clin Exp Res. 2010 ; 34: 1363-1375
135. Olive MF, Koenig HN, Nannini MA, et al. Stimulation of endorphin neurotransmission in the nucleus accumbens by ethanol, cocaine, and amphetamine. J Neurosci. 2001 ; 21: 1-5
136. Olmstead MC, Ouagazzal AM, Kieffer BL. Mu and delta opioid receptors oppositely regulate motor impulsivity in the signaled nose poke task. PLoS One. 2009 ; 4: e4410
137. Osborn MD, Lowery JJ, Skorput AGJ, et al. Life Sci. 2010 ; 86: 624-630
138. Oswald LM, Wand GS. Opioids and alcoholism. Physiol Behav. 2004 ; 81: 339-358 (Pubitemid 38670094)
139. Overstreet DH, Kampov-Polevoy AB, Rezvani AH, et al. Suppression of alcohol intake by chronic naloxone treatment in P rats: Tolerance development and elevation of opiate receptor binding. Alcohol Clin Exp Res. 1999 ; 23: 1761-1771
140. Pan ZZ. μ-Opposing actions of the κ-opioid receptor. Trends Pharmacol Sci. 1998 ; 19: 94-98
141. Peckys D, Landwehrmeyer G. Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNS: A 33P in situ hybridization study. Neurosci. 1999 ; 88: 1093-1135 (Pubitemid 28546992)
142. Petersen EN. The pharmacology and toxicology of disulfiram and its metabolites. Acta Psych Scand Suppl. 1992 ; 369: 7-13
143. Phillips TJ, Wenger CD, Dorow JD. Naltrexone effects on ethanol drinking acquisition and on established ethanol consumption in C57BL/6J mice. Alcohol Clin Exp Res. 1997 ; 21: 691-702 (Pubitemid 27272799)
144. Prescott CA, Kendler KS. Age at first drink and risk for alcoholism: a noncausal association. Alcohol Clin Exp Res. 1999 ; 23: 101-107 (Pubitemid 29068472)
145. Przewlocka B, Lasofi W, Przewtocki R. Repeated ethanol administration decreases prodynorphin biosynthesis in the rat hippocampus. Neurosci Lett. 1992 ; 134: 195-198
146. Rasmussen DD, Bryant CA, Boldt BM, et al. Acute alcohol effects on opiomelanocortinergic regulation. Alcohol Clin Exp Res. 1998 ; 22: 789-801 (Pubitemid 28292461)
147. Ray LA, Chin PF, Miotto K. Naltrexone for the treatment of alcoholism: Clinical findings, mechanisms of action, and pharmacogenetics. CNS Neurol Disorders - Drug Targets. 2010 ; 9: 13-22
148. Reid LD, Delconte JD, Nichols ML, et al. Tests of opioid deficiency hypotheses of alcoholism. Alcohol. 1991 ; 8: 247-257
149. Remmers AE, Clark MJ, Mansour A, et al. Opioid efficacy in a C6 glioma cell line stably expressing the human kappa opioid receptor. J Pharmacol Exp Ther. 1999 ; 288: 827-833 (Pubitemid 29119701)
150. Robbins TW, Everitt BJ. Functions of dopamine in the dorsal and ventral striatum. Sem Neurosci. 1992 ; 4: 119-127
151. Roberts AJ, Gold LH, Polis I, et al. Increased ethanol self-administration in delta-opioid receptor knockout mice. Alcohol Clin Exp Res. 2001 ; 25: 1249-1256 (Pubitemid 32868332)
152. Roberts AJ, McDonald JS, Heyser CJ, et al. mu-Opioid receptor knockout mice do not self-administer alcohol. J Pharmacol Exp Ther. 2000 ; 293: 1002-1008 (Pubitemid 30417870)
153. Robinson TE, Berridge KC. The neural basis of drug-craving: An incentive-sensitization theory of addiction. Brain Res Rev. 1993 ; 18: 247-291 (Pubitemid 23219500)
154. Rodríguez-Arias M, Aguilar MA, Manzanedo C, et al. Preclinical evidence of new opioid modulators for the treatment of addiction. Exp Opin Invest Drugs. 2010 ; 19: 977-994
155. Rohsenow DJ, Colby SM, Monti PM, et al. Predictors of compliance with naltrexone among alcoholics. Alcohol Clin Exp Res. 2000 ; 24: 1542-1549
156. Rutten K, De Vry J, Bruckmann W, et al. Effects of the NOP receptor agonist Ro65-6570 on the acquisition of opiate- and psychostimulant-induced conditioned place preference in rats. Eur J Pharmacol. 2010 ; 645: 119-126
157. Rutten K, De Vry J, Bruckmann W, et al. Pharmacological blockade or genetic knockout of the NOP receptor potentiates the rewarding effect of morphine in rats. Drug Alcohol Depend. 2011 ; 114: 253-256
158. Samson H, Doyle T. Oral ethanol self-administration in the rat: Effect of naloxone. Pharmacol Biochem Behav. 1985 ; 22: 91-99 (Pubitemid 15161531)
159. Sanchis-Segura C, Correa M, Miquel M, et al. Catalase inhibition in the arcuate nucleus blocks ethanol effects on the locomotor activity of rats. Neurosci Lett. 2005 ; 376: 66-70 (Pubitemid 40202939)
160. Seizinger BR, Bovermann K, Maysinger D, et al. Differential effects of acute and chronic ethanol treatment on particular opioid peptide systems in discrete regions of rat brain and pituitary. Pharmacol Biochem Behav. 1983 ; 18: 361-369
161. Sharpe A, Samson H. Effect of naloxone on appetitive and consummatory phases of ethanol self-administration. Alcohol Clin Exp Res. 2001 ; 25: 1006-1011 (Pubitemid 32656116)
162. Shippenberg TS. The dynorphin/kappa opioid receptor system: A new target for the treatment of addiction and affective disorders?. Neuropharmacol. 2009 ; 34: 247
163. Shippenberg T, Bals-Kubik R, Huber A, et al. Neuroanatomical substrates mediating the aversive effects of D-1 dopamine receptor antagonists. Psychopharmacology (Berl). 1991 ; 103: 209-214
164. Shippenberg TS, Herz A, Spanagel R, et al. Conditioning of opioid reinforcement: Neuroanatomical and neurochemical substrates. Annals NY Acad Sci. 1992 ; 654: 347-356
165. Shippenberg TS, Zapata A, Chefer VI. Dynorphin and the pathophysiology of drug addiction. Pharmacol Ther. 2007 ; 116: 306-321 (Pubitemid 47454747)
166. Simonin F, Gaveriaux-Ruff C, Befort K, et al. κ-Opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. Proc Natl Acad Sci. 1995 ; 92: 7006-7010
167. Spanagel R, Herz A, Shippenberg TS. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci. 1992 ; 89: 2046-2050
168. Starosta AN, Leeman RF, Volpicelli JR. The BRENDA model: Integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders. J Psychiatr Pract. 2006 ; 12: 80-89 (Pubitemid 44284090)
169. Steiner H, Gerfen CR. Role of dynorphin and enkephalin in the regulation of striatal output pathways and behaviour. Exp Brain Res. 1998 ; 123: 60-76 (Pubitemid 28495297)
170. Swift RM, Whelihan W, Kuznetsov O, et al. Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiat. 1994 ; 151: 1463-1467 (Pubitemid 24301690)
171. Takemori AE, Portoghese PS. Comparative antagonism by naltrexone and naloxone of mu, kappa, and delta agonists. Eur J Pharmacol. 1984 ; 104: 101-104 (Pubitemid 14006467)
172. Taqi MM, Bazov I, Watanabe H, et al. Prodynorphin CpG-SNPs associated with alcohol dependence: Elevated methylation in the brain of human alcoholics. Addict Biol. 2011 ; 16: 499-509
173. Tiffany ST, Conklin CA. Human models in craving research: A cognitive
174. Towell JF, Cho J, Roh BL, et al. Disulfiram and erythrocyte aldehyde dehydrogenase inhibition. Clin Pharmacol Ther. 1983 ; 33: 517-521 (Pubitemid 13093773)
175. Ubeda-Banon I, Novejarque A, Mohedano-Moriano A, et al. Projections from the posterolateral olfactory amygdala to the ventral striatum: Neural basis for reinforcing properties of chemical stimuli. BMC Neurosci. 2007 ; 8: 103-112
176. Report, Informal Expert Committee on the Craving Mechanism.. 1992 ;:
177. Ur E, Wright DM, Bouloux PMG, et al. The effects of spiradoline (U-62066E), a k-opioid receptor agonist, on neuroendocrine function in man. Br J Pharmacol. 1997 ; 120: 781-784 (Pubitemid 27122716)
178. Van Ree JM, Smyth DG, Colpaert FC. Dependence creating properties of lipotrophin c-fragment (β-endorphin): Evidence for its internal control of behaviour. Life Sci. 1979 ; 24: 495-502 (Pubitemid 9123394)
179. Verebey K, Mule SJ. Naltrexone pharmacology, pharmacokinetics, and metabolism: Current status. Amer J Drug Alcohol Abuse. 1975 ; 2: 357-363
180. Verheul R, van den Brink W, Geerlings P. A three-pathway psychobiological model of craving for alcohol. Alcohol Alcohol. 1999 ; 34: 197-222 (Pubitemid 29213715)
181. Volpicelli JR, Alterman AI, Hayashida M, et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psych. 1992 ; 49: 876-880
182. Volpicelli JR, Rhines KC, Rhines JS, et al. Naltrexone and alcohol dependence. Arch Gen Psych. 1997 ; 54: 737-742
183. Walker BM, Kissler JL. Dissociable Effects of Kappa-Opioid Receptor Activation on Impulsive Phenotypes in Wistar Rats. Neuropsychopharmacology. 2013 ;:
184. Walker BM, Koob GF. Pharmacological evidence for a motivational role of κ-opioid systems in ethanol dependence. Neuropsychopharmacol. 2008a ; 33: 643-652
185. Walker BM, Koob GF. Regarding 'Dynorphin is a downstream effector of striatal BDNF regulation of ethanol intake'. FASEB J. 2008b ; 22: 2113-2114
186. Wand G, Mccaul ME, Gotjen D, et al. Alcohol-dependent individuals have greater hypothalamic-pituitary-adrenal axis activation induced by naloxone compared with offspring without a family history of alcohol dependence. Alcohol Clin Exp Res. 2001 ; 25: 1134-1139 (Pubitemid 32758464)
187. Wand GS, McCaul M, Yang X, et al. The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacol. 2002 ; 26: 106-114 (Pubitemid 34075281)
188. Wand GS, Weerts EM, Kuwabara H, et al. The relationship between naloxone-induced cortisol and delta opioid receptor availability in mesolimbic structures is disrupted in alcohol-dependent subjects. Addict Biol. 2012 ; 18: 181-192
189. Ward RJ, Lallemand F, de Witte P. Biochemical and neurotransmitter changes implicated in alcohol-induced brain damage in chronic or 'binge drinking' alcohol abuse. Alcohol Alcohol. 2009 ; 44: 128-135
190. Watson BJ, Taylor LG, Reid AG, et al. Investigating expectation and reward in human opioid addiction with [(11) C]raclopride PET. Addict Biol. 2013 ;:
191. Wee S, Koob GF. The role of the dynorphin-κ opioid system in reinforcing effects of drugs of abuse. Psychopharmacology (Berl). 2010 ; 210: 121-135
192. Weerts EM, Kim YK, Wang GS, et al. Differences in δ- and μ-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects. Neuropsychopharmacol. 2008 ; 33: 653-665
193. Weerts EM, Wand GS, Kuwabara H, et al. Positron emission tomography imaging of mu- and delta-opioid receptor binding in alcohol-dependent and healthy control subjects. Alcohol Clin Exp Res. 2011 ; 35: 2162-2173
194. Weinshenker D, Schroeder J. There and back again: A tale of norepinephrine and drug addiction. Neuropsychopharmacol. 2007 ; 32: 1433-1451 (Pubitemid 46920149)
195. Williams TM, Daglish MRC, Lingford-Hughes A, et al. Brain opioid receptor binding in early abstinence from opioid dependence. Br J Psychiatry. 2007 ; 191: 63-69 (Pubitemid 47035183)
196. Williams TM, Davies SJ, Taylor LG, et al. Brain opioid receptor binding in early abstinence from alcohol dependence and relationship to craving: An [11C]diprenorphine PET study. Eur Neuropsychopharmacol. 2009 ; 19: 740-748
197. International Guide for Monitoring Alcohol Consumption and Related Harm. Geneva: WHO ; 2000:
198. Xiao C, Ye JH. Ethanol dually modulates GABAergic synaptic transmission onto dopaminergic neurons in ventral tegmental area: Role of mu-opioid receptors. Neurosci. 2008 ; 153: 240-248
199. Xiao C, Zhang J, Krnjević K, et al. Effects of ethanol on midbrain neurons: Role of opioid receptors. Alcohol Clin Exp Res. 2007 ; 31: 1106-1113 (Pubitemid 46934389)
200. Xuei X, Dick D, Flury-Wetherill L, et al. (2006) Association of the kappa-opioid system with alcohol dependence. Mol Psychiatry. 11: 1016-1024
201. Yancey-Wrona J, Dallaire B, Bilsky E, et al. 6B-naltrexol, a peripherally selective opioid antagonist that inhibits morphine-induced slowing of gastrointestinal transit: An exploratory study. Pain Med. 2011 ; 12: 1727-1737
202. Zadina JE, Hackler L, Ge L, et al. A potent and selective endogenous agonist for the μ-opiate receptor. Nature. 1997 ; 386: 499-502 (Pubitemid 27164076)
203. Zhang S, Yu L. Identification of dynorphins as endogenous ligands for an opioid receptor-like orphan receptor. J Biol Chem. 1995 ; 270: 22772-22776
204. Zhu J, Chen C, Xue J, et al. Cloning of a human κ-opioid receptor from the brain. Life Sci. 1995 ; 56: 201-207